Gut lumen toxins and metabolites

Gut lumen toxins and metabolites represent a heterogeneous group of substances, including uremic toxins, bacterial endotoxins, and metabolic byproducts like ammonia and trimethylamine N-oxide (TMAO), that are generated or accumulate within the gastrointestinal tract [1][2]. These molecules are often the result of microbial fermentation of dietary proteins or fibers and are normally maintained at low systemic levels by a functional intestinal barrier and renal or hepatic clearance [3]. In pathological states such as chronic kidney disease (CKD) or liver failure, the accumulation and subsequent systemic translocation of these metabolites contribute significantly to disease progression, cardiovascular complications, and neurotoxicity [4][5]. Therapeutic targeting of these substances involves the use of oral adsorbents (e.g., AST-120) or binders (e.g., Sevelamer) that sequester the toxins within the gut lumen, thereby preventing their absorption into the portal or systemic circulation [6]. This approach aims to reduce the metabolic burden on failing organs and mitigate the systemic inflammatory response associated with gut-derived toxemia [7].

Other names

Uremic toxinsGut-derived metabolitesIntestinal toxinsMicrobiota-derived metabolitesEndotoxinsBacterial metabolites

Physical adsorption, chemical sequestration, and reduction of microbial production to prevent systemic absorption of toxic metabolites [6][7].